drugset
Drugs / CRS-207
last change Jun 2025 re-read 2 minutes ago

CRS-207

Vaccine

Developed for
malignant pancreatic neoplasm · malignant pleural mesothelioma · pancreatic adenocarcinoma · esophageal adenocarcinoma · fallopian tube cancer · gastric adenocarcinoma · gastroesophageal junction adenocarcinoma · malignant epithelioid mesothelioma
+3 more · non-small cell lung carcinoma · ovarian adenocarcinoma · peritoneum cancer
Investigated by
Aduro Biotech, Inc. · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Bristol-Myers Squibb · Johns Hopkins University · Lustgarten Foundation · Merck Sharp & Dohme LLC
+5 more · National Cancer Institute (NCI) · American Association for Cancer Research · Anza Therapeutics, Inc. · Incyte Corporation · Stand Up To Cancer

Trials 10 · a red edge is where a trial was stopped

today NCT05014776 · Ph 2 NCT03190265 · Ph 2 NCT03122548 · Ph 2 NCT03175172 · Ph 2 NCT02575807 · Ph 1/2 NCT02243371 · Ph 2 NCT01675765 · Ph 1 NCT02004262 · Ph 2 NCT01417000 · Ph 2 NCT00585845 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01675765 Sep 2014 → Sep 2018 malignant pleural mesothelioma Aduro Biotech, Inc. Completed No outcome recorded
Phase 1 NCT00585845 Dec 2007 → Feb 2009 malignant epithelioid mesothelioma, non-small cell lung carcinoma, ovarian adenocarcinoma, pancreatic adenocarcinoma Anza Therapeutics, Inc. Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02575807 Mar 2016 → Apr 2018 fallopian tube cancer, peritoneum cancer Aduro Biotech, Inc. Terminated No outcome recorded
Phase 27 trials
Phase 2 NCT05014776 Aug 2022 → Apr 2024 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT03190265 Dec 2017 → Aug 2022 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT03122548 Aug → Dec 2017 esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Aduro Biotech, Inc. Terminated No outcome recorded
Phase 2 NCT03175172 May 2017 → Jan 2018 malignant pleural mesothelioma Aduro Biotech, Inc. Terminated No outcome recorded
Phase 2 NCT02243371 Jan 2015 → Jul 2017 pancreatic adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT02004262 Feb 2014 → Jan 2016 — Aduro Biotech, Inc. Completed No outcome recorded
Phase 2 NCT01417000 Sep 2011 → Oct 2016 malignant pancreatic neoplasm Aduro Biotech, Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03006302 Background Jan 2018 → Aug 2023 pancreatic adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as CRS 207 “This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of...” NCT00585845 ↗
11

“CRS-207 is a live-attenuated Listeria monocytogenes engineered to express mesothelin, a tumor-associated antigen highly expressed in MPM.” PMID 31263030 ↗ Jul 2019

NCT02004262 ↗

NCT05014776 ↗

NCT03122548 ↗

NCT03190265 ↗

NCT00585845 ↗

NCT01417000 ↗

NCT03006302 ↗

NCT02575807 ↗

NCT02243371 ↗

NCT03175172 ↗
Modality Vaccine “cancer vaccine CRS-207” NCT01675765 ↗
Route Intravenous “2-hour IV infusion” NCT00585845 ↗